| Recruiting | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential NCT06326008 | Beijing GoBroad Hospital | Phase 1 |
| Recruiting | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients NCT05745714 | Princess Maxima Center for Pediatric Oncology | Phase 1 / Phase 2 |
| Not Yet Recruiting | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL a NCT05779930 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Re NCT07070323 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL NCT06641024 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies NCT06316856 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Recruiting | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL NCT06445803 | Rong Tao | Phase 1 |
| Recruiting | CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With NCT06389305 | Beijing GoBroad Hospital | N/A |
| Recruiting | Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL P NCT06343090 | Beijing GoBroad Hospital | N/A |
| Recruiting | Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO NCT06025682 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia NCT06034561 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Recruiting | Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia NCT04881240 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological NCT05658640 | Princess Maxima Center for Pediatric Oncology | Phase 1 / Phase 2 |
| Recruiting | Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284 | University College, London | — |
| Withdrawn | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematol NCT05740449 | Princess Maxima Center for Pediatric Oncology | Phase 1 / Phase 2 |
| Recruiting | Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664 | Andrew E. Place, MD | Phase 1 |
| Recruiting | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults NCT05310591 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Recruiting | Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lympho NCT05705570 | Nelson Hamerschlak | Phase 1 |
| Completed | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children NCT04325841 | Beijing Boren Hospital | Phase 2 |
| Unknown | Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD NCT05137860 | Hospital General de Mexico | Phase 4 |
| Unknown | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT NCT05066958 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Active Not Recruiting | Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse NCT04475731 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignan NCT04603872 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL NCT04888442 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Terminated | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL NCT04049383 | Medical College of Wisconsin | Phase 1 |
| Completed | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/R NCT03957915 | Institut Paoli-Calmettes | EARLY_Phase 1 |
| Terminated | Study of Sequential CAR-T Cell Treating Leukemia Children NCT04340154 | Beijing Boren Hospital | Phase 2 |
| Completed | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children NCT04340167 | Beijing Boren Hospital | Phase 2 |
| Completed | CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children NCT04224571 | Chinese University of Hong Kong | Phase 2 |
| Active Not Recruiting | Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute NCT03573700 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Completed | Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) NCT03751072 | Group for Research in Adult Acute Lymphoblastic Leukemia | — |
| Terminated | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic NCT03705507 | University of Birmingham | Phase 1 / Phase 2 |
| Terminated | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia NCT03515200 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT NCT03389035 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 1 / Phase 2 |
| Completed | GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia NCT01518517 | ERYtech Pharma | Phase 2 / Phase 3 |